Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | NY-ESO-1-c259T |
Trade Name | |
Synonyms | GSK3377794|GSK-3377794|GSK 3377794 |
Drug Descriptions |
NY-ESO-1-c259T (GSK3377794) are autologous, engineered T cells that recognize the cancer testis antigen, CTAG1B (NY-ESO-1), which may result in an immune response against CTAG1B and/or CTAG2 (LAGE-1) expressing cancer cells (PMID: 26193344). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C121379 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + Cyclophosphamide + Decitabine + NY-ESO-1-c259T | Aldesleukin Cyclophosphamide Decitabine NY-ESO-1-c259T | 0 | 1 |
Cyclophosphamide + Fludarabine + NY-ESO-1-c259T | Cyclophosphamide Fludarabine NY-ESO-1-c259T | 0 | 1 |
NY-ESO-1-c259T | NY-ESO-1-c259T | 0 | 4 |
NY-ESO-1-c259T + Pembrolizumab | NY-ESO-1-c259T Pembrolizumab | 0 | 2 |